$EGRX (Eagle Pharmaceuticals Inc.)

$EGRX {{ '2015-12-24T12:40:48+0000' | timeago}} • Announcement

$EGRX said FDA has approved Docetaxel Injection, Non-Alcohol Formula. $EGRX entered into exclusive licensing agreement with Teikoku Pharma USA in Oct. to market, sell and distribute Docetaxel Injection in the U.S. $EGRX estimates that annual sales of generic docetaxel are about $75MM.

$EGRX {{ '2017-10-17T12:47:27+0000' | timeago}} • Announcement

Pharma company $EGRX said the US Patent and Trademark Office has issued a new patent related to its Ryanodex formulation. The patent is directed to the treatment of non-normothermia associated with recreational usage of Ryanodex. The patent will expire in June 2022.

$EGRX {{ '2017-07-26T17:30:38+0000' | timeago}} • Announcement

$EGRX has received a Complete Response Letter from the FDA, requesting the company to conduct an additional clinical trial for RYANODEX for exertional heat stroke. $EGRX added that RYANODEX remains approved for the treatment of hyperthermia in conjunction with appropriate supportive measures.

$EGRX {{ '2017-07-25T15:28:28+0000' | timeago}} • Announcement

$EGRX issued a statement that it has not yet received correspondence from the US FDA regarding its 505(b)(2) New Drug Application for Ryanodex (dantrolene sodium) for the treatment of exertional heat stroke. The PDUFA date was July 23, 2017.

$EGRX {{ '2017-05-15T11:56:45+0000' | timeago}} • Announcement

$EGRX appointed Pete Meyers as CFO, effective May 15, 2017. Meyers will also serve as the company's principal financial officer and principal accounting officer, effective May 15, 2017. Meyers currently serves on the BoD of Prima BioMed Ltd, where he chairs the Audit Committee.

$EGRX {{ '2017-05-08T19:30:51+0000' | timeago}} • Webcast

With regard to malignant hyperthermia managing therapy Ryanodex, $EGRX is getting ready to start dosing patients, probably have the first patient dose next month. $EGRX expects to have the study completely recruited in next 6 months and go into phase 2 or phase 3 study before this year.

$LLY {{ '2017-05-08T19:18:08+0000' | timeago}} • Webcast

With regard to the $LLY's chemotherapy drug Pemetrexed, $EGRX said it has a PDUFA date at the end of October and the company is doing everything it can to optimize the value of the asset. $EGRX said it is doing everything possible to find the appropriate value in the product.

$EGRX {{ '2017-05-08T12:03:26+0000' | timeago}} • Announcement

In 1Q17, $EGRX product sales rose to $15.3MM from $14.1MM a year ago. Royalty revenue jumped to $36.5MM from $9.5MM, while license and other revenue improved to $25.0MM compared to last year's $6.0MM. As of quarter end, Eagle had $27.7MM in cash and cash equivalents and $84.7MM in net accounts receivable.

$EGRX {{ '2017-05-08T11:59:27+0000' | timeago}} • Announcement

$EGRX's total revenue expanded more than 2.5 times to $76.8MM in 1Q17, as the specialty pharma firm shifted to profit with a net income of $22.9MM from last year's loss of $0.9MM. Earnings were $1.42 per diluted share from a loss of $0.06 per share, as Eagle saw hyperthermia drug Ryanodex' sales soar 132% to $4.4MM in the quarter.

$EGRX {{ '2017-03-16T14:30:14+0000' | timeago}} • Announcement

$EGRX has appointed Richard Edlin, Vice Chair, Chair of the Litigation Practice in New York, to its BoD, and as a member of the Board’s Nominating and Corporate Governance Committee, effective March 17, 2017.

$EGRX {{ '2017-02-22T14:26:23+0000' | timeago}} • Announcement

$EGRX said 4 additional patents have been issued related to Bendeka by the United States Patent and Trademark Office (USPTO), with expiry date of January 2031 and March 2033. The USPTO has allowed a total of 14 patents in the Bendeka family of patents expiring from 2026 to 2033, 4 of which will issue over next few months.

$EGRX {{ '2017-01-03T13:39:46+0000' | timeago}} • Announcement

$EGRX submitted a new drug application to the U.S. Food and Drug Administration (FDA). This requests FDA approval of $EGRX's ready-to-dilute (RTD) Pemetrexed Injection product for the treatment of Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer, and Mesothelioma (in combination with cisplatin).

$EGRX {{ '2016-12-19T13:26:32+0000' | timeago}} • Announcement

$EGRX said it appointed David Pernock as its President and Chief Commercial Officer, effective Jan. 2017. Pernock will be responsible for all commercial strategy and execution for $EGRX's growing product portfolio.

$EGRX {{ '2016-11-11T12:42:55+0000' | timeago}} • Announcement

$EGRX has agreed to acquire Arsia Therapeutics. $EGRX will pay approx. $30MM, of which $27.3MM will be in cash and $2.7MM will be in $EGRX common stock. $EGRX has also agreed to pay up to $48MM in additional payments on completion of certain milestones, for total potential payments of $78MM. The deal is expected to close within the next week.

$EGRx {{ '2016-11-09T15:39:04+0000' | timeago}} • Webcast

$EGRx reported that it is building a good amount of cash. If the company hits the next sales milestone in middle of January, it expects to get $25MM from $TEVA. The company is very bullish on purchasing its stock. With no debt, $EGRX is looking at acquisitions on the product side.

$EGRX {{ '2016-11-09T15:24:31+0000' | timeago}} • Webcast

$EGRX expects sales and marketing expenses in 2016 to ramp up as new product launches gain momentum. The company expects to receive approx. $100MM or more from $TEVA over the next few months.

$EGRX {{ '2016-11-09T15:11:23+0000' | timeago}} • Webcast

$EGRX reported that it will receive a $40MM milestone payment from its extended licensing agreement with $TEVA. The company received an upfront payment of $1.75MM and $EGRX's royalty rate will increase from 20% to 25% for the sale of Bendeka injection. Bendeka is an injection for the treatment of patients with a type of cancer.

$EGRX {{ '2016-11-09T12:43:49+0000' | timeago}} • Announcement

$EGRX said it extended its licensing agreement with Teva Pharmaceutical Industries Ltd. to include certain territories outside the US and Canada. The Centers for Medicare & Medicaid Services set up a unique J-Code (J9034) for Bendeka product, effective Jan. 1, 2017, the company said.

$EGRX {{ '2016-11-09T12:40:51+0000' | timeago}} • Announcement

$EGRX posted 3Q16 earnings of $12MM, or $0.73 per diluted share, compared to a loss of $10.2MM from a year ago. Revenue grew 563% to $37.8MM, helped by sales growth in Bendeka, Non-Alcohol Docetaxel Injection, Argatroban, and Ryanodex products.

$EGRX {{ '2015-12-24T12:40:48+0000' | timeago}} • Announcement

$EGRX said FDA has approved Docetaxel Injection, Non-Alcohol Formula. $EGRX entered into exclusive licensing agreement with Teikoku Pharma USA in Oct. to market, sell and distribute Docetaxel Injection in the U.S. $EGRX estimates that annual sales of generic docetaxel are about $75MM.

$EGRX {{ '2015-12-24T12:39:10+0000' | timeago}} • Announcement

Specialty pharmaceutical company $EGRX said the U.S. Food and Drug Administration has approved Docetaxel Injection, Non-Alcohol Formula for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. $EGRX will begin shipping Docetaxel Injection in Jan. 2016.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
MACK (Merrimack Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
EGRX (Eagle Pharmaceuticals Inc.)
Wednesday, November 8 2017 - 1:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
INFI (Infinity Pharmaceuticals, Inc.)
Tuesday, November 7 2017 - 1:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
SPPI (Spectrum Pharmaceuticals, Inc.)
Thursday, November 2 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
INCY (Incyte Corporation)
Tuesday, October 31 2017 - 2:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, October 26 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, October 25 2017 - 8:30pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm

AlphaGraphics you may like